Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: a randomized controlled trial.

OBJECTIVE: Myocardial injury during cardiac surgery is a major cause of perioperative morbidity and mortality. We determined whether perioperative statin therapy is cardioprotective in patients undergoing noncoronary artery cardiac surgery and the potential mechanisms. METHODS AND RESULTS: One hundred fifty-one patients undergoing noncoronary artery cardiac surgery were randomly assigned to either a statin group (n=77) or a control group (n=74). Simvastatin (20 mg) was administered preoperatively and postoperatively. Plasma were analyzed for troponin T, isoenzyme of creatine kinase, C-reaction protein, interleukin-6, interleukin-8, creatinine, and blood urea nitrogen. Cardiac echocardiography was performed. Endothelial nitric oxide synthase (eNOS), Akt, p38, heat shock protein 90, caveolin-1, and nitric oxide (NO) in the heart were detected. Simvastatin significantly reduced plasma troponin T, isoenzyme of creatine kinase, C-reaction protein, blood urea nitrogen , creatinine, interleukin-6, interleukin-8, and the requirement of inotropic postoperatively. Simvastatin increased NO production, the expression of eNOS and phosphorylation at serine1177, phosphorylation of Akt, expression of heat shock protein 90, heat shock protein 90 association with eNOS and decreased eNOS phosphorylation at threonine 495, phosphorylation of p38, and expression of caveolin-1. Simvastatin also improved cardiac function postoperatively. CONCLUSIONS: Perioperative statin therapy can improve cardiac function and renal function by reducing myocardial injury and inflammatory response through activating Akt-eNOS and attenuating p38 signaling pathways in patients undergoing noncoronary artery cardiac surgery. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT01178710.

N-Terminal Pro-B-Type Natriuretic Peptide in Tricuspid Valve Replacement.

The aim of the present study was to retrospectively investigate the prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in tricuspid valve replacement (TVR). A total of 73 TVR patients who had NT-proBNP measured on the first postoperative morning during a period of 10 years from February 2008 to December 2018 were included in the study. The endpoint was postsurgery all-cause in-hospital mortality. The outcome-based cut-point optimization was performed using X-tile software. NT-proBNP with the maximum χ2 score and the minimum P value will be used as the optimal cut-point. Kaplan-Meier analysis and log-rank test were adopted to calculate and compare survival rates stratified by tertiles and the cut-point. Predictive capabilities of NT-proBNP were tested using univariable and multivariable Cox regression. Overall, 20 (27.3%) in-hospital deaths occurred. Postsurgery hospital stay was 21 days (interquartile range, 16-32 day). NT-proBNP were divided into low (<1262 pg/mL), medium (1262-4003 pg/mL), and high (≥4003 pg/mL) tertiles. The optimal cut-off point determined using X-tile was 3639 pg/mL. Kaplan-Meier analysis revealed a strong association between worse survival and elevated NT-proBNP expressed as tertiles (log-rank P = 0.002) and stratified by optimal cut point (log-rank P < 0.001). Multivariable Cox survival analysis demonstrated that NT-proBNP was a strong predictor of mortality (logNT-proBNP hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.33-3.37; P = 0.002). In NT-proBNP tertiles model, multivariable Cox survival analysis showed that patients in the medium and high NT-proBNP tertiles had 6.32-fold (adjusted HR, 7.32; 95% CI, 0.76-70.69; P = 0.085) and 16.11-fold (adjusted HR, 17.11; 95% CI, 1.92-152.68, P = 0.011) increased risk for mortality, respectively, compared with patients in the low tertile. Elevated postoperative NT-proBNP level is a potential independent and strong in-hospital postsurgery mortality risk factor in TVR, thus may serve as a useful surrogate marker for risk-stratification.

Mid-Term Outcome after Tricuspid Valve Replacement.

OBJECTIVE: To evaluate the mid-term survival rate after tricuspid valve replacement (TVR). METHODS: We retrospectively studied 110 consecutive patients who underwent TVR from January 2007 to November 2017. A survival analysis was performed with the Kaplan-Meier method and the log-rank test. RESULTS: The median survival was 65.81 months. Mean age was 50 (range 39 to 59) years. Forty-eight patients (43.6%) were male, and 62 patients (56.4%) were female. Most of the patients (78.5%) were categorized into the New York Heart Association (NYHA) functional classes III/IV. Seventy-two patients (65.5%) had isolated TVR. Six-three patients (57.3%) had previously undergone heart surgery. The Kaplan-Meier survival rates at one year, three years, and five years were 59.0%±5%, 52.0%±6%, and 48.0%±6%, respectively. A Cox regression analysis demonstrated that the risk factors for mid-term mortality were advanced NYHA class (hazard ratio [HR] 2.430, 95% confidence interval [CI] 1.099-5.375, P=0.028), need for continuous renal replacement therapy (CRRT) treatment (HR 3.121, 95% CI 1.610-6.050, P=0.001), and need for intra-aortic balloon pump (IABP) treatment (HR 3.356, 95% CI 1.072-10.504, P=0.038). CONCLUSION: In TVR, impaired cardiac function before the operation and a need for CRRT or IABP treatment after the operation is independently associated with increased mid-term mortality.

Analysis of risk factors and establishment of a risk prediction model for cardiothoracic surgical intensive care unit readmission after heart valve surgery in China: A single-center study.

BACKGROUND: Valvular heart disease is one of the most frequent and challenging heart diseases worldwide. The incidence of complications and cardiothoracic surgical intensive care unit (CSICU) readmission after cardiac valve surgery is high. Because CSICU readmission is costly and adversely impacts the quality life, reducing the risk of CSICU readmission has become one of the main focuses of health care. OBJECTIVE: To explore the risk factors for CSICU readmission and to establish a risk prediction model for CSICU readmission in heart valve surgical patients. METHODS: A total of 1216 patients who had undergone cardiac valvular surgery between January 2016 and August 2017 at the First Affiliated Hospital of Sun Yat-sen University were assigned as the development and validation data sets. Data from 824 patients in the development data set were retrospectively analyzed to identify potential risk factors with univariate analysis. Multivariate logistic regression was used to determine the independent risk factors of CSICU readmission, which served as the basis for our prediction model. The calibration and discrimination of the model were assessed by the Hosmer-Lemeshow (H-L) test and the area under the receiver operating characteristic (ROC) curve, respectively. RESULTS: Six preoperative variables (age ≥ 65, previous chronic lung disease, prior cardiac surgery, left ventricular ejection fraction (LVEF) ≤ 40%, 40% < LVEF ≤ 50%, and New York Heart Association (NYHA) classification III/IV), two intraoperative variables (multiple valve repair/replacement and cardiopulmonary bypass time ≥ 180 min), and five postoperative variables (cardiac arrest, acute respiratory distress syndrome, pneumonia, deep sternal wound infection, and renal failure) were independent risk factors of CSICU readmission. Our risk prediction model, which was established based on the above-mentioned risk factors, had robust discrimination and calibration in both the development and validation data sets. CONCLUSION: The prediction model established in our study is a simple, objective, and accurate scoring system, which can be used to predict the risk of CSICU readmission and assist researchers with designing intervention strategies to prevent CSICU readmission.

Early thrombolytic failure in a patient with massive pulmonary embolism combined with multiple organ dysfunction syndrome: what next?

Carbon monoxide (CO) poisoning, the most frequent type of poisoning, alters hemodynamics and creates tissue hypoxia that ultimately leads to thromboembolism. We herein describe a previously healthy 17-year-old male patient who developed acute CO poisoning while bathing in the same room as a gas heater. He was first treated with urokinase thrombolytic therapy at a local hospital, which proved ineffective. The patient was admitted to our hospital with unstable circulation and was diagnosed with massive pulmonary embolism combined with multiple organ dysfunction syndrome. His Acute Physiology and Chronic Health Evaluation II score was 22, and his Sequential Organ Failure Assessment score was 15. We faced a difficult decision regarding whether to perform surgical embolectomy or to repeat the thrombolysis. We opted to repeat the thrombolysis with successful results. Our experience may help clinicians manage similar cases in the future.

Relationship and mechanism of Kv2.1 expression to ADH secretion in rats with heart failure.

OBJECTIVE: To explore the mechanisms of Kv2.1 on the secretion of ADH in rats with heart failure. METHODS: In the animal study, 70 healthy male SD rats were selected. Ligation of coronary heart failure model surgery was performed in 60 rats and sham surgery was performed in the other 10 rats. Q-PCR was used to detect the mRNA expression of Kv2.1 in hypothalamus and heart. The protein expression of Kv2.1 and ADH was detected by western blot. In the cell culture study, hypothalamic neurons were cultured and divided into 7 groups. The mRNA expression of Kv2.1 and ADH was detected by Q-PCR. The protein expression of Kv2.1, CamKII, phosphorylation SynapsinI, dephosphorylation SynapsinI and ADH was detected by western blot. RESULTS: Compared with the control group of heart failure, LVEDD, LVESD, LVEDV and LVESV were significantly decreased (P < 0.01), and LVEF and LVFS were significantly increased (P < 0.01) in the Kv2.1 agonist group; in the Kv2.1 inhibitor group, LVEDD, LVESD, LVEDV and LVESV were significantly increased (P < 0.01), and LVEF and LVFS were significantly decreased (P < 0.01). In cell culture study, after the different concentrations of Kv2.1 inhibitor gradient down the expression of Kv2.1, intracellular Ca2+ concentration gradient increased (P < 0.01), CamKII and phosphorylation of SynapsinI protein expression gradient increased (P < 0.01), dephosphorylation of SynapsinI protein expression gradient decreased (P < 0.01), and the ADH mRNA and protein expression of gradient increased (P < 0.01). CONCLUSIONS: Kv2.1 agonist can prevent the calcium overload by reducing the intracellular Ca2+ concentration, so that the phosphorylation of SynapsinI reduces and exocytosis in hypothalamic neurons is inhibited, which ease the secretion of ADH.

[Prognostic factors of myasthenic crisis after extended thymectomy in patients with generalized myasthenia gravis].

OBJECTIVE: To investigate the prognostic factors of myasthenic crisis after extended thymectomy in patients with generalized myasthenia gravis (MG). METHODS: Extended thymectomy was performed on 176 patients with generalized MG, 74 males and 102 females, aged 4 - 67, of which 36 experienced postoperative myasthenic crisis and required prolonged mechanical ventilation. The relations among the age, sex, preoperative course of disease, pathologic type of thymus, Osserman classification, history of infection during 1 month preoperatively, history of myasthenic crisis 1 month preoperatively, thymoma, preoperative daily dose of pyridostigmine, preoperative steroid use, operation time, intra-operative blood loss, and intra-operative pleura injury and postoperative myasthenia crisis were analyzed. RESULTS: Univariate analysis showed that bulbar symptoms (OR = 8.494, P = 0.001), history of myasthenic crisis 1 month preoperatively (OR = 5.667, P = 0.000), thymoma (OR = 2.147, P = 0.047), Osserman types III and IV (OR = 0.459, P = 0.000), history of infection during 1 month preoperatively (OR = 3.30, P = 0.038), large pre-operative dose of pyridostigmine (OR = 1.019, P = 0.001), long operation time (OR = 1.012, P = 0.034), and more blood loss (186 ml +/- 163 ml) (OR = 1.004, P = 0.012), were all prognostic factors or postoperative myasthenic crisis. However, multivariate logistic regression analysis revealed that preoperative bulbar symptoms (OR = 7.709, P = 0.003), history of infection during 1 month preoperatively (OR = 4.582, P = 0.037), history of myasthenic crisis 1 month preoperatively (OR = 4.526, P = 0.001, large pre-operative dose of pyridostigmine (OR = 1.016, P = 0.001) were prognostic factors of postoperative myasthenic crisis. CONCLUSION: Preoperative bulbar symptoms, history of preoperative myasthenic crisis, history of preoperative infection, and large preoperative dose of, pyridostigmine are all independent influencing factors of postoperative myasthenic crisis. Ample preoperative care may prevent postoperative myasthenic crisis in the patients with such factors.

Surgical intervention for advanced valvular heart disease in 227 cases.

BACKGROUND: Although the results of surgical treatment in cardiac valve disease continue to improve, the postoperative mortality rate and the rate of complications in patients with advanced valvular heart disease (AVHD) are still very high. We did this retrospective study to summarize the surgical experience of heart valve replacement for patients with AVHD and discuss effective ways to improve the surgical outcome. METHODS: From January 1994 to October 2003, surgical procedures of heart valve replacement were performed on 227 (136 men and 91 women) patients with AVHD in our Department of Cardiothoracic Surgery. The clinical data of all patients were collected and analysed. Patients' age ranged from 10 years to 77 years. In preoperative cardiac function grading, 157 cases were NYHA III and 70 cases NYHA IV. Fifty-one patients had had cardiac operations. The ultrasonic cardiac graphs showed that 145 patients suffered from moderate or severe pulmonary hypertension and 73 had combined giant left ventricle. Mitral valve replacement was performed in 32 cases, aortic valve replacement in 90, tricuspid valve replacement in 1, combined mitral and aortic replacement in 103 and combined mitral and tricuspid replacement in 1. Nineteen patients also received surgical corrections for other minor abnormalities during the operations. A logistic model was established to evaluate the influence of perioperative factors on the mortality rate. RESULTS: The operative mortality rate was 13.2% (30/227). The main causes of death included multiple organ dysfunction syndrome (MODS), low cardiac output syndrome and ventricular fibrillation. From the results of the binary noncounterpart multivariate logistic regression, the following statistically significant factors were found to influence the operative mortality rate: redo operation, age >/= 55 years, preoperative NYHA cardiac function grading, extracorporeal circulation time >/= 120 minutes and postoperative usage of GIK (glucose, insulin and potassium) solution. All factors were risk ones except postoperative application of GIK. The Hosmer-Lemeshow goodness of fit coefficient of this model was 0.976. CONCLUSIONS: The risk factors associated with postoperative mortality rate in the patients with AVHD were redo operation, age >/= 55 years, preoperative NYHA cardiac function grading and extracorporeal circulation time >/= 120 minutes. Postoperative usage of GIK acted as a kind of metabolic therapy and will improve the recovery for patients with AVHD. Active perioperative management and care will play a very important role in reducing the operative risk and improving the short term outcome of surgical treatment for the patients with AVHD.

Mid-term outcome after tricuspid valve replacement

Abstract Objective: To evaluate the mid-term survival rate after tricuspid valve replacement (TVR). Methods: We retrospectively studied 110 consecutive patients who underwent TVR from January 2007 to November 2017. A survival analysis was performed with the Kaplan-Meier method and the log-rank test. Results: The median survival was 65.81 months. Mean age was 50 (range 39 to 59) years. Forty-eight patients (43.6%) were male, and 62 patients (56.4%) were female. Most of the patients (78.5%) were categorized into the New York Heart Association (NYHA) functional classes III/IV. Seventy-two patients (65.5%) had isolated TVR. Six-three patients (57.3%) had previously undergone heart surgery. The Kaplan-Meier survival rates at one year, three years, and five years were 59.0%±5%, 52.0%±6%, and 48.0%±6%, respectively. A Cox regression analysis demonstrated that the risk factors for mid-term mortality were advanced NYHA class (hazard ratio [HR] 2.430, 95% confidence interval [CI] 1.099-5.375, P=0.028), need for continuous renal replacement therapy (CRRT) treatment (HR 3.121, 95% CI 1.610-6.050, P=0.001), and need for intra-aortic balloon pump (IABP) treatment (HR 3.356, 95% CI 1.072-10.504, P=0.038). Conclusion: In TVR, impaired cardiac function before the operation and a need for CRRT or IABP treatment after the operation is independently associated with increased mid-term mortality.